Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO ADALIMUMAB INDUCTION REGIMENS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE AND EVIDENCE OF MUCOSAL ULCERATION

Intervention/treatment:
HUMIRA
Medical condition:
CROHN'S DISEASE
Protocol code:
M14-115
Control number:
170849
Status:
Closed
Approved:
January 13, 2014
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02065570
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Medical Services
Organization
AbbVie
Phone:
800-633-9110
Sponsor
ABBVIE CORPORATION

Locations

Alberta

University of Alberta /ID# 119022
Edmonton, Alberta, T6G 2X8
University of Calgary Cumming School of Medicine Adult Cystic Fibrosis Clinic /ID# 119017
Calgary, Alberta, T2N 4Z6

Manitoba

Winnipeg Regional Health Authority /ID# 119015
Winnipeg, Manitoba, R3A 1R9

Nova Scotia

Qe Ii Hsc /Id# 127115
Halifax, Nova Scotia, B3H 1V7

Ontario

London Health Sciences Centre - University Hospital /ID# 119026
London, Ontario, N6A 5A5
Medicor Research Inc /ID# 119024
Greater Sudbury, Ontario, P3E 5M4
Toronto Digestive Disease Asso /ID# 119019
Vaughan, Ontario, L4L 4Y7

Quebec

Montreal General Hospital - McGill University Health Center /ID# 119025
Montreal, Quebec, H3G 1A4

Results

See the results from the trial NCT02065570. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?